www.StockMarketingInc.com: Great News For Our Subscibers!! ECOF,GEOI,SAFM,KNXA,BSDM,NYMX:: Sign Up Today!!

STOCK MARKETING INC PRESENTS : (PINKSHEETS: ECOF) Eco2 Forests Inc., (NASDAQ: GEOI) GeoResources, Inc., (NASDAQ: SAFM) Sanderson Farms, Inc., (NASDAQ: KNXA) Kenexa Corp., (NASDAQ: BSDM) BSD Medical Corp., (NASDAQ: NYMX) Nymox Pharmaceutical Corp.

www.StockMarketingInc.com

To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com

email us!! info@StockMarketingInc.com or call 1-866-583-8960

------------------------------------------------------------------------------------------------------------------------------------------------------------

(PINKSHEETS: ECOF - Eco2 Forests Inc.)

LATEST NEWS!!

ECO2 Forests Projects Receives Vanuatu Government Approval

SACRAMENTO, CA and QUEENSLAND, AUSTRALIA, Feb 09, 2010 -- ECO2 Forests Inc. (PINKSHEETS: ECOF), is pleased to announce that is has received Government approval from the Vanuatu Investment Promotion Authority (VIPA) to conduct their Reforestation Project on the island of Malakula.

Approval from VIPA, the national government authority, officially recognizes that the ECO2 Forests Malakula project meets the criteria set by the Government that the project is of benefit to the people and environment of Vanuatu and is compliant with all regulations.

The VIPA approval and support expressed by the Malampa Council for ECO2 Forests now allows for the Environmental Impact Assessment (EIA), the final step in the planning and approval process, to be completed.

The Government of Vanuatu stipulates that all foreign companies wishing to trade, work or establish any sort of enterprise in Vanuatu apply for and receive VIPA approval. Central to the approval process, VIPA assesses the benefit and impact the project has with the environment and the growth of Vanuatu and its people, including the employment it will create.

ECO2 Forests intends to create in excess of 300 full time jobs, sourced from the local community on Malakula, an island currently limited in employment opportunities. These permanent positions are forecast to expand as the project grows and is planned to continue over multiple generations. ECO2 Forests intends to deliver world class education in sustainable forestry and forest preservation to entire families and communities in Vanuatu.

In the approval letter from the VIPA Board, dated 15th January 2010, it was noted "that these forests remove large amounts of Carbon Dioxide from the atmosphere and are a significant contributor to the mitigation of global warming." "In November 2009, we visited with representatives of the National Advisory Committee on Climate Change, the then Minister of Agriculture and senior representatives of the Malampa Provincial Council, where positive discussions focussed on future opportunities of working with the local communities. These meetings attended by ECO2 executives were centered on ensuring positive economic, environmental, educational and employment outcomes for Vanuatu and its communities, which is specifically consistent with our own E4 Philosophy," Chief Operating Officer Ray Smith said.

"In addition to the approval of the Vanuatu Investment Promotion Authority, we have presented the project to the full provincial council and custom land owners and they indicated in writing their support for the project. Project information has also been supplied to other government officials interested in supporting the project," added Smith.

"The approval and support of the government and provincial counsel recognizes the long-term positive social, economic and environmental impact that the ECO2 Forests project will have for Vanuatu." "Infrastructure developments and upgrades for the local community will aim to provide improved access and facilities. Incorporating cultural aesthetics in all design and development will enable communities to maintain their traditions and way of life," ECO2 Founder Martin Tindall commented.

The Malakula Reforestation Project is intended to provide environmental benefits for the entire country and the world through the sequestration of over 7 million tons of carbon dioxide from the atmosphere in every seven year harvest cycle. The sustainable nature of the reforestation project will also negate the need to log old growth and rain forests in Vanuatu, preserving the natural beauty of the Vanuatu islands for generations to come.

About ECO2 Forests Inc.

ECO2 Forests Inc. (PINKSHEETS: ECOF) is an international sustainable forestation company focused on reforestation of previously damaged and deforested land and the saving of existing threatened forests through sustainable reforestation, afforestation and avoided deforestation projects for the generation and sale of carbon credits and a sustainable timber to global markets.

Headquartered in Sacramento, California, the Company has adopted an 'E4 Philosophy' to achieve positive Environmental, Economic, Employment and Educational outcomes through its reforestation projects.

For more information please visit www.eco2forests.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: GEOI - GeoResources, Inc.)

LATEST NEWS!!

GeoResources, Inc. to Present at The Oil and Services Conference(TM) VIII -- San Francisco

HOUSTON, Feb 09, 2010 -- GeoResources, Inc., (NASDAQ: GEOI), today announced that it will participate in The Oil and Services Conference(TM) VIII being held at the City Club of San Francisco on February 17-19, 2010.

Robert J. Anderson, Vice-President of Business Development, Acquisitions and Divestitures is scheduled to present on Wednesday, February 17, 2010 at 3:10 pm Pacific Time. A live webcast will be available on The Oil and Services Conference(TM) VIII website at http://www.investorcalendar.com/CEPage.asp?ID=155185. The Company's presentation materials will also be available on the Company's website at www.georesourcesinc.com.

About GeoResources, Inc. GeoResources, Inc. is an independent oil and gas company engaged in the acquisition and development of oil and gas reserves through an active and diversified program which includes purchases of reserves, re-engineering, and development and exploration activities, currently focused in the Southwest, Gulf Coast, and the Williston Basin. For more information, visit our website at www.georesourcesinc.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: SAFM - Sanderson Farms, Inc.)

LATEST NEWS!!

Sanderson Farms, Inc. to Broadcast Its First-Quarter 2010 Conference Call Live on the Internet

LAUREL, Miss., Feb 09, 2010 -- Sanderson Farms, Inc. (NASDAQ: SAFM) today announced that it will provide an online Web simulcast of its fiscal first-quarter 2010 earnings conference call on Tuesday, February 23, 2010. During this call, management will comment on Sanderson Farms' financial and operational results for the first quarter ended January 31, 2010.

The live broadcast of Sanderson Farms' conference call will begin at 10:00 a.m. Central Time, 11:00 a.m. Eastern Time on February 23. An online replay will be available approximately two hours following the conclusion of the live broadcast and will continue through March 2, 2010. Links to these events may be found at the investor relations section of the Company's website, www.sandersonfarms.com, and from www.earnings.com. Those without Internet access may listen to the call by dialing (800) 533-9703 (Confirmation Code 2145370).

Sanderson Farms, Inc. is engaged in the production, processing, marketing and distribution of fresh and frozen chicken and other prepared food items. Its shares trade on the NASDAQ Global Select Market under the symbol SAFM.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: KNXA - Kenexa Corp.)

LATEST NEWS!!

Kenexa Relationship With Air Force Takes Off -- Recruiting Efforts Expanded

Successful Pilot Programs Result in Randolph Air Force Base Signing on for Recruitment Consulting Services

WAYNE, PA, Feb 09, 2010 -- Kenexa(R) (NASDAQ: KNXA), a global provider of business solutions for human resources, today announced the expansion of its relationship with the U.S. Air Force to deliver university and community outreach services for the Air Force Personnel Center Scientist and Engineer Career Field located at Randolph Air Force Base near San Antonio, Texas. Leveraging the successful recruiting program that Kenexa created for five Air Force bases across the country, Kenexa will establish a robust recruiting system to attract and fill critically needed Science, Technology, Engineering and Mathematics (STEM) individuals by creating a hiring pipeline with new college graduates and experienced engineers and scientists for the Air Force.

Saul Ortigoza, scientist and engineer career program administrator, Air Force, stated, "The STEM Program is delighted to continue and broaden our working relationship with Kenexa. Along with assisting the STEM Program goals and objective, Kenexa is assisting in the hiring of Civilian Scientists and Engineers for the Air Force as a whole. We have more than 11,000 scientists and engineers in our career field and Kenexa's efforts allow us to compete more effectively with the private sector for these talented people." Leveraging the existing USAJOBS Web site, Kenexa will establish new services and programs to attract a higher caliber of candidates for Randolph Air Force Base. Using its proven university and community outreach process, which includes creating printed collateral and email campaigns, working with professional societies, developing internship and minority outreach programs, establishing a presence at career fairs, and instituting relationships with universities, Kenexa will build a pipeline of high-quality graduates and experienced professionals for the base.

Andrew Jackson, global head of Kenexa's government solutions practice, added, "Kenexa is honored to support recruiting for the U.S. Air Force. By implementing our best practice recruitment processes, we are able to improve the effectiveness and efficiency of its recruiting and retention efforts. Based on the spectacular results from these programs, nearly 20,000 candidates are being tracked in the system and time-to-fill has been cut in half, since partnering with Kenexa. We are looking forward to helping Randolph Air Force Base locate high-caliber candidates and use their recruiting resources to the best possible effect." With Kenexa's unique ability to operationalize an organization's employment branding, Randolph Air Force Base will benefit from a proactive marketing campaign that specifically targets the top-notch graduates and professionals who are critical to the success of the organization. During the course of the five-year engagement, Kenexa will work to develop relationships with deans, department heads and school representatives at 17 universities with strong engineering programs, including California Polytechnic State University San Luis Obispo, California State University, Embry-Riddle Aeronautical University, University of California, Northridge and Fresno, and the University of Puerto Rico, Mayaguez.

About Kenexa Kenexa(R) provides business solutions for human resources. We help global organizations multiply business success by identifying the best individuals for every job and fostering optimal work environments for every organization. For more than 20 years, Kenexa has studied human behavior and team dynamics in the workplace, and has developed the software solutions, business processes and expert consulting that help organizations impact positive business outcomes through HR. Kenexa is the only company that offers a comprehensive suite of unified products and services that support the entire employee lifecycle from pre-hire to exit. Additional information about Kenexa and its global products and services can be accessed at www.kenexa.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: BSDM - BSD Medical Corp.)

LATEST NEWS!!

BSD Medical Reports Initiation of a Phase III Study on Pancreatic Cancer Using the BSD-2000 Hyperthermia System in Combination with Chemotherapy

SALT LAKE CITY, Feb 09, 2010 -- BSD Medical Corporation (NASDAQ: BSDM) reports initiation of a randomized, multicenter Phase III clinical study using the BSD-2000 Hyperthermia System in combination with chemotherapy for the treatment of pancreatic cancer patients after R0/R1 surgical resection of their tumor (complete removal or only microscopic tumor remaining). The coordinating investigator is Rolf D. Issels, MD PhD, Department of Medical Oncology, Klinikum Grosshadern, Munich University Medical School, Munich, Germany. The Phase III study, which is being sponsored by the European Society for Hyperthermic Oncology (ESHO), will compare hyperthermia with chemotherapy (gemcitabine) to chemotherapy (gemcitabine) alone.

The Phase III study was initiated following completion of a Phase II study that utilized chemotherapy and hyperthermia to treat 21 inoperable pancreatic patients who were resistant to or had failed previous chemotherapy gemcitabine treatments, a patient population with a dire prognosis. There was one complete response (complete disappearance of the tumor), 3 partial responses (more than 50% tumor reduction), and 7 patients with stable disease (no tumor growth). The study results demonstrated a low toxicity rate and an overall survival of 16.9 months. By comparison, the median survival for inoperable pancreatic cancer patients after gemcitabine treatment is only 6 months. The Phase III study, which is being sponsored by the European Society for Hyperthermic Oncology (ESHO), will compare hyperthermia with chemotherapy (gemcitabine) to chemotherapy (gemcitabine) alone.

Pancreatic cancer is one of the deadliest and hardest to treat cancers and is the fourth leading cause of cancer-related death. There were an estimated 42,470 Americans and 60,000 Europeans diagnosed with pancreatic cancer during 2009 and approximately 80% are inoperable. The median survival period from the time of diagnosis until death is 3.5 to 6 months, depending on treatment, and less than 5 percent survive to five years. Advanced pancreatic cancer patients currently have few treatment options. The study is scheduled to open for patient enrollment in March 2010. The following clinical sites will participate in the clinical study: Klinikum Grosshadern of Ludwigs-Maximilans-Universitat Munchen, HELIOS Schlossbergklinik Oberstaufen, Rotkreuzkrankenhaus Munchen, Universitatsklinikum Dusseldorf, Klinikum Mannheim of Heidelberg University Medical School, Universitatsklinikum Erlangen, Universitatsklinikum Freiburg, Universitatsklinikum Tubingen, and Charite University Medical School Berlin (all Germany); Kantonsspital Aarau AG (Switzerland); and Ospedale Borgo Trento Verona (Italy).

About the European Society for Hyperthermic Oncology ESHO was organized to promote research relating to the use of hyperthermia in cancer therapy and to facilitate the exchange of information among multiple disciplines regarding the study of heat in the treatment of cancer.

About BSD Medical Corporation BSD Medical Corporation is a leading developer of systems used to deliver precision-focused microwave/RF energy to diseased sites in the body, including cancer. Its treatments are used to kill cancer directly and increase the effectiveness of companion radiation treatments for certain tumors. The BSD-2000 is restricted to investigational use in the United States. For further information, visit BSD Medical's website at www.BSDMedical.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: NYMX - Nymox Pharmaceutical Corp.)

LATEST NEWS!!

Nymox Provides Update on Pivotal Phase 3 Trials for BPH Drug

HASBROUCK HEIGHTS, N.J., Feb 9, 2010 -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The first Safety Monitoring Committee meeting of 2010 for the Phase 3 U.S. pivotal trials of NX-1207 indicated an acceptable ongoing safety evaluation of the trials to date. Patient recruitment and trial activities for pivotal U.S. studies NX02-0017 and NX02-0018 are proceeding at over 60 well-known urology investigative sites throughout the U.S. The participating centers continue to evaluate and enroll patients and accrual is progressing well. The current Phase 3 trials incorporate specific protocol design recommendations made by the FDA at the earlier EOP2 meeting with the Company. For more information about the NX-1207 Phase 3 clinical trials, please go to www.clinicaltrials.gov or contact Nymox at info@nymox.com.

NX-1207 has been shown to improve the signs and symptoms of BPH, producing improvements which reached statistical significance compared to double-blinded placebo and study controls. A single administration of NX-1207 2.5 mg has produced on average improvements in the standardized BPH symptom score (8-10 points) that were approximately double that reported for currently approved BPH drugs (3-5 points). NX-1207 involves a new targeted approach to the treatment of BPH. The drug is administered by a urologist in an office setting directly into the zone of the prostate where the enlargement occurs. The injection takes only a few minutes and involves little or no pain or discomfort. NX-1207 has not been found to have the sexual, blood pressure, or other side effects of the approved drugs.

Follow-up studies have shown clinical efficacy effects in men lasting up to 5 years after a single treatment. At one year after a single treatment, the median improvement in BPH Symptom Score was 9.0 points in the AUA Symptom Score (p<.003).

In a recently published peer-reviewed publication entitled, NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia" written by Neal Shore MD FACS, Medical Director of the Carolina Urologic Research Center, Myrtle Beach, SC, in Expert Opinion on Investigational Drugs, the author wrote: "Regarding existing oral drug therapies, the use of NX-1207 would obviate daily and lifelong compliance issues as well as the ongoing concerns of polypharmacy facing the elderly and the attendant risk for drug-drug interactions. In comparison to office-based MIST options, the transrectal injection approach afforded by NX-1207, both anesthetic/analgesic free as well as catheter free, will be quite compelling to most patients. If the ongoing Phase III trials can duplicate the success seen in earlier trials, for both efficacy and safety, then the administration of NX-1207 should be expected to significantly impact the current pattern of treatment options employed by urologists for their patients with BPH". The paper is available online at http://informahealthcare.com/doi/abs/10.1517/ 13543780903555196.

BPH is one of the most commonly diagnosed diseases in the male U.S. population. The condition can seriously impact the health and quality of life of older men and can lead to acute urinary retention, incontinence, and other serious consequences. It is estimated that 50% of men in their 50s have pathological signs of prostatic hyperplasia and from 26 to 46% of men between the ages of 40 to 79 years suffer from moderate to severe urinary problems and symptoms associated with BPH.

More information about Nymox is available at www.nymox.com

------------------------------------------------------------------------------------------------------------------------------------------------------------

About StockMarketingInc.com

StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.

CONTACT: StockMarketingInc.com e-mail: info@StockMarketingInc.com Tel: +1 866 583 8960

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Related terms: acquisition, agriculture, air force, australia, business, california, cancer, career, clinical, community, conference, consulting, disease, drugs, earnings, education, email, e-mail, employment, energy, engineering, environment, environmental impact, exploration, food, forestry, germany, government, human resources, internet, investment, investment opinion, italy, market, marketing, medical, men, nasdaq, oil and gas, online, pennsylvania, pharmaceuticals, pilot, pipeline, population, products, puerto rico, queensland, research, science, switzerland, technology, timber, trade, trial, university, vanuatu, web, writing